news
Merck KGaA and Pfizer advance avelumab clinical development programme
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
List view / Grid view
Pfizer
news
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
news
COMP issues positive opinion for ODD for avelumab in MCC
1 December 2015 | By Victoria White
An official decision on the Ophran Drug Designation is expected from the European Commission in December...
news
EC approves label update for Pfizer’s Xalkori in NSCLC
26 November 2015 | By Victoria White
The EC has approved a label update to expand the use of Xalkori (crizotinib) to first-line treatment of adults with ALK-positive NSCLC...
article
More pharma M&A to come?
25 November 2015 | By Garry White, Chief Investment Commentator, Charles Stanley
Viagra maker Pfizer announced on Monday that it would purchase Allergan, the Irish maker of Botox, for about $160bn – the biggest deal ever in the healthcare sector. Could more mega-mergers be in prospect?
news
Pfizer and Allergan agree mega merger
23 November 2015 | By Victoria White
The combined company, to be named Pfizer plc, will be the biggest drug maker in the world by sales...
news
Servier exercises options to acquire worldwide rights to UCART19
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
news
Pfizer’s Phase 3 Xalkori NSCLC trial meets primary objective
18 November 2015 | By Victoria White
Xalkori demonstrated significantly prolonged progression-free survival in previously untreated East Asian patients with ALK-positive advanced NSCLC...
news
FDA grants Breakthrough Therapy designation to avelumab for MCC
18 November 2015 | By Victoria White
Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody...
news
Phase III study of avelumab in NSCLC starts
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
news
Pfizer and Allergan considering a merger
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
news
FDA grants Breakthrough Therapy designation to inotuzumab ozogamicin
19 October 2015 | By Victoria White
Pfizer’s investigational antibody-drug conjugate inotuzumab ozogamicin has received Breakthrough Therapy designation for acute lymphoblastic leukaemia...
news
FDA grants Fast Track designation to avelumab for Merkel cell carcinoma
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
news
Sayana Press becomes first contraceptive in the UK for self-injection
24 September 2015 | By Victoria White
Sayana Press combines a long-acting, reversible, contraceptive with an all-in-one prefilled, single-use, non-reusable Uniject injection system...
news
Top-line Phase 3 results for ulcerative colitis treatment tofacitinib announced
22 September 2015 | By Victoria White
Both Phase 3 studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo...
